An antibody against DR4 (TRAIL-R1) in combination with doxorubicin selectively kills malignant but not normal prostate cells

被引:26
作者
Voelkel-Johnson, C [1 ]
机构
[1] Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC 29403 USA
关键词
tumor necrosis factor inducing ligand (TRAIL); DR4 (TRAIL-R1); DR5 (TRAIL-R2); doxorubicin; apoptosis;
D O I
10.4161/cbt.2.3.398
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Prostate cancer is a major health problem among American men and new treatment approaches are needed. Tumor necrosis factor related apoptosis-inducing ligand (TRAIL/Apo2L) is a death ligand that can induce apoptosis in some but not all cancer cells. Resistance to TRAIL-mediated apoptosis can be overcome by radiation or chemotherapy. The effect of doxorubicin/TRAIL combination therapy was compared among PC3, normal prostate epithelial (PrEC) and stromal (PrSC) cells and cell viability measured by MTS assay. Combination of doxorubicin and TRAIL caused cytotoxicity in all cells tested, although PrSC were more resistant. There was no correlation between TRAIL phenotype and expression of c-FLIP, caspases or TRAIL decoy receptors, although PrSC failed to express DR4. A DR4-specific antibody, which behaved as an agonist in combination with doxorubicin, selectively induced cell death in malignant but not normal prostate cells. Although normal PrEC expressed DR4 as determined by western blot, flow cytometry revealed that only maligant prostate cancer cells (PC3, JCA-1) and not PrEC's exhibited DR4 surface expression. Therefore, combination of doxorubicin and an antibody to DR4 might have therapeutic potential for the treatment of prostate cancer by selectively targeting malignant prostate cells.
引用
收藏
页码:283 / 288
页数:6
相关论文
共 48 条
[1]  
Abe K, 2000, ANN NY ACAD SCI, V926, P52
[2]   Safety and antitumor activity of recombinant soluble Apo2 ligand [J].
Ashkenazi, A ;
Pai, RC ;
Fong, S ;
Leung, S ;
Lawrence, DA ;
Masters, SA ;
Blackie, C ;
Chang, L ;
McMurtrey, AE ;
Hebert, A ;
DeForge, L ;
Koumenis, IL ;
Lewis, D ;
Harris, L ;
Bussiere, J ;
Koeppen, H ;
Shahrokh, Z ;
Schwall, RH .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (02) :155-162
[3]   Sensitization of resistant lymphoma cells to irradiation-induced apoptosis by the death ligand TRAIL [J].
Belka, C ;
Schmid, B ;
Marini, P ;
Durand, E ;
Rudner, J ;
Faltin, H ;
Bamberg, M ;
Schulze-Osthoff, K ;
Budach, W .
ONCOGENE, 2001, 20 (17) :2190-2196
[4]   Improving the efficacy of antibody-based cancer therapies [J].
Carter, P .
NATURE REVIEWS CANCER, 2001, 1 (02) :118-129
[5]   Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy [J].
Chinnaiyan, AM ;
Prasad, U ;
Shankar, S ;
Hamstra, DA ;
Shanaiah, M ;
Chenevert, TL ;
Ross, BD ;
Rehemtulla, A .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (04) :1754-1759
[6]   Isotype-dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4 [J].
Chuntharapai, A ;
Dodge, K ;
Grimmer, K ;
Schroeder, K ;
Marsters, SA ;
Koeppen, H ;
Ashkenazi, A ;
Kim, KJ .
JOURNAL OF IMMUNOLOGY, 2001, 166 (08) :4891-4898
[7]   Expression of tumour necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptors and sensitivity to TRAIL-induced apoptosis in primary B-cell acute lymphoblastic leukaemia cells [J].
Clodi, K ;
Wimmer, D ;
Li, Y ;
Goodwin, R ;
Jaeger, U ;
Mann, G ;
Gadner, H ;
Younes, A .
BRITISH JOURNAL OF HAEMATOLOGY, 2000, 111 (02) :580-586
[8]   Synergistic induction of apoptosis by the combination of TRAIL and chemotherapy in chemoresistant ovarian cancer cells [J].
Cuello, M ;
Ettenberg, SA ;
Nau, MM ;
Lipkowitz, S .
GYNECOLOGIC ONCOLOGY, 2001, 81 (03) :380-390
[9]   The novel receptor TRAIL-R4 induces NF-κB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain [J].
Degli-Esposti, MA ;
Dougall, WC ;
Smolak, PJ ;
Waugh, JY ;
Smith, CA ;
Goodwin, RG .
IMMUNITY, 1997, 7 (06) :813-820
[10]   Sensitivity to TRAIL/APO-2L-mediated apoptosis in human renal cell carcinomas and its enhancement by topotecan [J].
Déjosez, M ;
Ramp, U ;
Mahotka, C ;
Krieg, A ;
Walczak, H ;
Gabbert, HE ;
Gerharz, CD .
CELL DEATH AND DIFFERENTIATION, 2000, 7 (11) :1127-1136